Clinical Study Results
Did any adverse reactions happen during this study?
Standard dose Low dose
of BGF MDI of BFF MDI GFF MDI BFF MDI
(out of 2,144 (out of 2,124 (out of 2,125 (out of 2,136
participants) participants) participants) participants)
How many participants had adverse
10.4% (222) 9.4% (200) 7.1% (151) 10.3% (220)
reactions?
How many participants had serious
1.3% (27) 1.7% (37) 0.9% (19) 1.3% (27)
adverse reactions?
How many participants stopped 1.5% (33) 1.1% (24) 1.3% (28) 1.8% (38)
taking study treatment because of
adverse reactions?
What serious adverse reactions happened during this study?
The most common serious adverse reaction was worsening of COPD symptoms.
The table below shows the serious adverse reactions that happened in more than 1 participant.
There were other serious adverse reactions, but these happened in fewer participants.
Most common serious adverse reactions during the study
Standard
dose of BGF Low dose
MDI of BGF MDI GFF MDI BFF MDI
(out of 2,144 (out of 2,124 (out of 2,125 (out of 2,136
Serious adverse reaction participants) participants) participants) participants)
Worsening of COPD symptoms 0.7% (15) 0.9% (20) 0.5% (10) 0.7% (16)
Pneumonia 0.4% (8) 0.1% (3) 0.1% (3) 0.2% (4)
Irregular heartbeat 0.0% (0) 0.1% (3) 0.0% (0) 0.0% (0)
Heart attack 0.0% (0) 0.0% (0) 0.1% (2) 0.0% (0)
Heart suddenly stops beating, also known as
0.1% (1) 0.0% (0) 0.1% (1) 0.0% (0)
cardiac arrest
Clogging or narrowing of the blood vessels 0.1% (2) 0.0% (0) 0.0% (0) 0.0% (0)
There were less than 0.1% of participants who died from serious adverse reactions during the
study. This was 6 out of 8,529 participants.
• Less than 0.1% of the participants who took the standard dose of BGF MDI died from serious
adverse reactions. This was 3 out of 2,144 participants.
• None of the 2,124 participants who took the low dose of BGF MDI died from serious adverse
reactions.
10